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The overall 5-year survival rate for woman diagnosed with breast cancer has 
increased significantly over the last 20 years. However, prognosis for women with stage 
IV, metastatic disease remains very poor. Women diagnosed with stage 0-III breast 
cancer have above an 85% chance of survival over a 5-year period while women 
diagnosed with stage IV breast cancer have a 5-year survival of less than 30%. A better 
understanding of the molecular mechanisms driving aggressive breast cancer is essential 
for the potential discovery of more targeted therapies to increase the survival rates for 
women diagnosed with stage IV breast cancer. 
  Previous members of the Stein/Lian laboratory profiled 113 novel, small RNA 
molecules in various breast cancer cell models to identify potential candidates for testing. 
In this study, we examine a novel class of short, non-coding RNA molecules called 
tRNA-derived small RNAs (tsRNAs). These molecules are 18-48 nucleotides long and 
are cleaved RNA fragments generated during tRNA maturation. We identified two 
candidate tsRNAs, ts-2 and ts-112, that have relatively low expression in the normal-like 
breast epithelial cell line, MCF10A, and increase in expression as breast cancer becomes 
more aggressive, with the highest expression in the MCF10CA1a cell line. 
Because ts-2 and ts-112 are upregulated in MCF10CA1a cells compared to 
MCF10A cells, we hypothesized that ts-2 and ts-112 promote breast cancer disease 
progression. In this study, inhibitors of ts-2 and ts-112 were transfected into 
MCF10CA1a cells and mimics were transfected into MCF10A cells to further understand 
the role of these molecules in certain cancer phenotypes. Assays were performed to 
assess the affect of tsRNA on cell growth, death, migration, invasion, and any cell cycle 
changes after ts-2 and ts-112 gain or loss of function  
We observed a decrease in cell growth rate over time after ts-2 and ts-112 
inhibition in MCF10CA1a cells. In trypan blue exclusion growth curve assays, tsRNA 
inhibited populations had fewer cells than mock and negative control populations over a 
72-hour time course. Further, we observed parallel results with CCK-8 assays for cell 
proliferation and in a flow cytometry analysis of the cell cycle. The percent of cells in S 
phase increased in the ts-2 and ts-112 inhibited populations when compared to the mock 
and negative control, indicating that cells are blocked in S phase after tsRNA inhibition. 
We observed an increase in cell growth rate over time after ts-2 and ts-112 
overexpression in MCF10A cells. We performed trypan blue exclusion growth curve 
assays and saw an increase in population growth over a 72-hour time course. In parallel, 
similar results were observed using a CCK-8 cell proliferation assay, where ts-2 and ts-
112 overexpressed populations had an increase in cell proliferation compared to mock 
and negative control. Cell death, migration and invasion were unchanged when ts-2 and 
ts-112 levels were manipulated in these cell models.  
Our results reveal the role of ts-2 and ts-112 in breast cancer and provide a better 
understanding of the molecular mechanisms related to a worsened prognosis for women 
with stage IV disease compared to women with stage 0-III disease. Future studies could 
potentially lead to the use of tsRNAs as blood biomarkers for cancer risk and diagnosis or 
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CHAPTER 1: INTRODUCTION 
1.1 Cancer Facts and Statistics  
Cancer is defined as the uncontrolled growth of cells with the ability to invade 
surrounding tissue (1). According to the American Cancer Society, 1,806,590 new cases 
of cancer will be diagnosed in the United States in 2020. As the second leading cause of 
death in the country, cancer will take an estimated 606,520 lives this year (1). Although 
cancer is common, some tissue types are affected more often than others. Aside from 
basal cell carcinoma, a type of skin cancer, men are at the highest risk to develop prostate 
cancer (20% of all new cases) and women are at the highest risk to develop breast cancer 
(30% of all new cases). In the United States, 1 in 8 women will be diagnosed with breast 
cancer at some point in her life (1). In 2020, it is estimated that there will be 276,480 new 
cases of breast cancer in the United States, and 42,170 deaths (1).  
1.2 Breast Cancer Overview 
Breast cancer arises after genetic mutations occur in mammary epithelial cells that 
lead to deregulated control of cell growth and tissue homeostasis. While every subtype of 
cancer is different, cancer cells often share phenotypic characteristics such as the ability 
to evade apoptosis, insensitivity to anti-growth signals, self-sufficiency in growth signals, 
sustained angiogenesis, limitless replicative potential and capability of invading 
surrounding tissue (2). Cancer cells are often invasive and rapidly dividing. It is 
important to identify the presence of cancer and to begin a treatment regimen in a patient 
as early as possible to ensure the best outcome. 
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Early detection is important for improving outcomes.  Early detection often is 
associated with limited disease progression which is easier to treat compared to later 
stage disease. Regular breast exams, ultrasounds, mammograms, screening magnetic 
resonance imaging (MRI) and biopsies are key screening and diagnosis techniques for 
breast cancer. According to the National Comprehensive Cancer Network guidelines for 
breast cancer screening and diagnosis, every woman age 45 and above is recommended 
to have a yearly mammogram. Mammography is X-ray imaging of the breast tissue used 
to screen for breast cancer. It has been reported that women who are screened for breast 
cancer by mammography have a 60% reduced risk of death caused by the disease over a 
10 year period (3). While mammography is often the preferred screening route, some 
genetically predisposed, young, premenopausal women have dense breast tissue, which 
alters the effectiveness of mammography detection. Often, MRIs are a more sensitive 
method of screening, used in this subset of patients who are considered high risk for the 
disease (4).  
1.3 Staging of Breast Cancer  
Breast tumors are categorized into five stages (0-IV). Staging of the cancer allows 
both the physician and the patient to understand the prognosis of the disease as well as 
informs individual treatment strategy development.  
Non-invasive breast cancers are classified as stage 0. Commonly referred to as 
carcinoma in situ (CIS), stage 0 breast cancer is defined as a population of abnormal cells 
within the breast tissue that have the potential of developing into cancer. CIS can be 
further divided into two categories based on tumor location: lobular carcinoma in situ 
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(LCIS) and ductal carcinoma in situ (DCIS). As their names suggest, LCIS originates in 
the breast lobules and DCIS originates in ductal system of the breast tissue. As LCIS 
rarely progresses to become invasive disease, prophylactic tamoxifen, a selective 
estrogen receptor modulator, is recommended for treatment. The National 
Comprehensive Cancer Network reports a 4-10x increased risk of developing invasive 
breast cancer when LCIS is present (5). Unlike LCIS, DCIS often progresses into 
invasive breast cancer (5). DCIS is treated by either lumpectomy or total mastectomy and 
reconstruction surgery, according to the most recent National Comprehensive Cancer 
Network guidelines. There will be approximately 48,530 new cases of DCIS diagnosed in 
American women this year (1).  
Stage I and II breast cancer are both considered early-stage, invasive disease. 
Typically, stage I tumors are 2 centimeters or less and remain localized to the breast 
tissue. Stage II tumors range from 2-5 centimeters in size and also remain localized to the 
breast tissue itself (6). Treatment for stage I and II breast cancer typically involves a 
combination of breast conserving surgery and radiation therapy (7). Breast conserving 
surgery involves the removal of a tumor, but not the healthy breast tissue and is often 
referred to as a lumpectomy. 
Stage III breast cancer is often described as locally advanced. These tumors are 
larger than 5 centimeters and considered inoperable (7). Treatment typically involves 
removing all breast tissue in attempt to restrain any current or future cancer growth in the 
area, a procedure known as a mastectomy. 
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Stage IV breast cancer involves metastasis, which is when cancer cells migrate 
and invade surrounding tissue, often into the blood or lymphatic systems. Metastatic 
disease has the worst prognosis among all stages. While chemotherapy is used for 
treatment of this disease stage, radiation is also used to manage disease-related pain (7).  
1.4 Survival Rates Based on Disease Stage 
Characterization of a patient’s breast cancer into stages helps determine the 
prognosis for each individual. That said, the five-year survival rate for a woman with 
breast cancer is determined by the stage of her disease. In the year 2000, the five-year 
survival rate for women, black or white, with stage 0 disease was 89-97%, and increased 
in the year 2020 to 96-99%. For stage I-II disease, the five-year survival rate for black 
and white women was 63-78% in 2000 and has increased to 77-87% in 2020. Stage III 
disease had a five-year survival rate of only 14-22% in black and white women in the 
year 2000 and has only increased to 20-29% in the year 2020.  While the less aggressive 
stages have increased survival rates, the five-year survival rate of stage IV disease 
remains less than 30% (1, 8). There remains a need for a better understanding of the 
molecular mechanisms driving stage IV disease to improve the overall survival rates of 
patients diagnosed with aggressive breast cancer. 
1.5  Hormone Receptors and Tumor Subtypes 
Besides clinical staging, receptors expressed by breast cancer cells allow for 
molecular characterization of the cancer. The presence of specialized proteins, namely 
estrogen receptor (ER), progesterone receptor (PR), and receptor tyrosine-protein kinase 
ERBB-2 (HER2), either inside the cells or on the cell surface, are important in deciding 
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treatment for an individual patient. Knowing what specialized proteins are expressed in 
an individual cancer cell population allows targeted treatment with drugs designed to 
bind and alter the proteins in order to slow down or kill the cells. While estrogen and 
progesterone receptors are proteins located within the cell (9), HER2 is a transmembrane 
protein (10). As their names suggest, the ligand for ER is estrogen, the ligand for PR is 
progesterone. These hormones enter the cell through simple diffusion in order to bind to 
and activate their receptors. The ligand for HER2 is epidermal growth factor (EGF) and 
EGF can bind a ligand binding site on the outside of the cell to activate various 
downstream effects. Active HER2 leads to activation of STAT, Ras, and Src which are 
responsible for cellular functions that promote cancer - like proliferation, differentiation, 
and motility. Often in cancer, HER2 is overexpressed and activated independently of 
ligand binding (10), which causes downstream effects such as increased growth, which 
can help to explain why cancer cells continually grow and divide.  
 Depending on receptor expression in an individual patient’s cancer, it can be 
described as the following: estrogen/progesterone receptor positive (ER/PR+) or 
estrogen/progesterone receptor negative (ER/PR-) and receptor tyrosine-protein kinase 
ERBB-2 positive (HER2+) or receptor tyrosine-protein kinase ERBB-2 negative (HER2-
). To determine which hormone receptors are present in an individual patient’s cancer, 
immunohistochemistry is performed to specifically stain the receptors of interest. A 
cancer is considered ER+ if the immunohistochemistry stains 1-100% of the cells present 
in the tested sample. If less than 1% of the cell nuclei are stained, the cancer is considered 
ER- (11). If a patient is ER+, endocrine therapy can be used for treatment. Selective 
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endocrine receptor modulators (SERMs), like tamoxifen, are used for treatment of ER+ 
breast cancer to slow cancer growth and shrink tumors (12). For this reason, ER+ breast 
cancer is associated with a more favorable outcome than ER- breast cancer (13). Testing 
for the presence of PR is done in the same fashion, but results of this test help determine 
prognosis, and not treatment regimen (11). HER2 levels are sometimes increased in 
breast cancers, leading to increased growth factor signaling and therefore elevated cancer 
cell growth rates. Levels of HER2 on the cell surface should be measured in patients with 
breast cancer to determine if they would benefit from treatment with certain monoclonal 
antibodies. These antibodies are specifically designed to bind to the growth factor 
receptor, resulting in inhibition of HER2 activity, such as slowed cancer cell growth (6). 
Further, some patients do not express any hormone receptors, and are considered to have 
triple negative breast cancer, which is the most difficult to treat (14). 
There are four intrinsic molecular subtypes of breast cancer: luminal A, luminal 
B, HER2 enriched, and basal-like. Luminal A is ER/PR+ and HER2-, and luminal B is 
ER/PR+ and HER2+/-. These types are determined based on proliferation and luminal 
pathways. As their names suggest, proliferation pathways are cell cycle related and 
luminal pathways are hormone-regulated pathways. Luminal B tumors express proteins 
related to cell cycle regulation at higher levels and have lower expression of progesterone 
receptor than Luminal A tumors. HER-2 enriched breast cancers express high levels of 
HER-2 and other proliferation-related genes but are ER/PR-. Basal-like breast cancers are 
usually ER-/PR-/HER2- and involve high expression of proliferation genes at the basal 
layer of the skin (15, 16).  
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1.6 Breast Cancer Cell Models 
Despite the knowledge of signaling pathways like those involving ER and HER2, 
there remains a lack of understanding of the molecular mechanisms driving aggressive 
breast cancer. Cell lines derived from breast tissue isolated from healthy or cancerous 
women are well established to model normal-like and tumor cell behavior. Researchers 
are better able to relate in vitro studies to in vivo effects by categorizing cell lines based 
on the presence of cell surface hormone receptors (17). Commonly studied cell lines 
include the MDA-MB-231, MCF7, and MCF10 cell lines. MDA-MB-231 cells are 
representative of triple negative breast cancer. MCF7 cells represent a subset of breast 
cancers that are ER/PR+ and HER2-. MCF10 cells are an ER low/HER2+ breast cancer 
cell model (17).  The MCF10 set of cell lines is commonly used to study breast cancer 
progression, modeling the normal-like mammary epithelium as well as different stages of 
cancer initiation, development, and progression (18). Obtained from subcutaneous 
mastectomy tissue of a 36-year old healthy female, the MCF10 cell line was 
immortalized into suspension cells, MCF10M, and adherent cells, MC10A.   Because of 
their adherent nature, MCF10A cells are contact dependent, and therefore similar to 
normal mammary epithelial cells. Because of this, MCF10A cells were used for further 
transformations. MCF10A cells were transformed with mutated H-RAS followed by 
serial xenografts to generate the MCF10AT1 cell line, representing early stage, estrogen 
receptor negative breast cancer. The MCF10CA1a was further derived from subsequent 




1.7 Noncoding RNA Molecules in Breast Cancer  
Studies over the last two decades have established that noncoding RNA molecules 
(ncRNAs) are important in the normal development of a cell. Long ncRNAs are over 200 
nucleotides long and have established roles in chromatin rearrangement, histone 
modification, modification in alternative splicing, and the regulation of gene expression 
as well as functions in tumorigenesis (19). Small ncRNAs are shorter than 200 
nucleotides and have also been discovered to have a role in promoting cancer initiation 
and progression (20). Recently, a novel class of small ncRNA has been identified that 
distinguishes normal-like cells from breast cancer cells (20). 

















Figure 1.1: TsRNA Biogenesis. 
TsRNAs are formed during the maturation of tRNA from pre-tRNA. RNAse P cleaves 
the 5’ end first, then RNAse Z cleaves the 3’ end of pre-tRNA and the cleaved, short non-
coding RNA fragment known as tsRNA is 18-48 nucleotides in length. Pre-tRNA 




It has been recently discovered that tRNA-derived small RNA (tsRNA) molecules 
are dysregulated in breast cancer. TsRNAs are small, non-coding RNA molecules formed 
during the maturation process of tRNA. Pre-tRNA is cleaved in the nucleus or 
mitochondria by RNaseP and RNaseZ, enzymes which cleave nucleotides from the 5’ 
and 3’ end, respectively. Cleavage from the 3’ end by RNaseZ results in a 16-48 
nucleotide short, noncoding RNA molecule, known as tsRNA (22).  Preliminary studies 
on tsRNAs show that while some tsRNAs, like ts-36, promote cancer cell proliferation 
(23), others like ts-47, slow it down (24). It has also been reported that tsRNAs are 
associated with argonaut proteins and function like microRNAs, a well-studied class of 
small ncRNA, in some cancers (25, 26).     
When tsRNAs were discovered in the 1970s, it was believed that tsRNA 
molecules were simply biproducts of tRNA maturation. However, recent studies have 
identified important roles for tsRNA in regulating cellular function, both in healthy and 
disease states (22). Cellular functions and biological roles for which tsRNAs are 
important include: regulating mRNA stability, inhibiting translation initiation and 
elongation, regulating ribosome biogenesis, regulating RNA reverse transcription, 
regulating apoptosis, and functioning as a novel epigenetic factor (22). Levels of tsRNAs 
are abnormal in various stressful cellular conditions, or disease states, including cancer. 
Since tsRNA levels are upregulated in some cancer, it is suggested that they play a 
protective role in cell survival. It has been reported that tsRNAs can serve as targets for 
tumor therapy as well as detection strategies for cancer diagnosis via patient urine or 
serum samples (22). 
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To elucidate the molecular mechanisms driving breast cancer, the Stein/Lian 
research group profiled 113 established tsRNA in MCF10A, MCF10AT1, MCF7, 
MCF10CA1a, and MDA-MB-231 cell lines and H9 female human embryonic stem cells 
(hESC). Two tsRNAs, ts-2 and ts-112, have relatively low levels in the normal-like, 
mammary epithelial MCF10A cells and high levels in MCF10CA1a and MDA-MB-231 
aggressive breast cancer cell lines (20). Further, H9 hESCs express high levels of ts-2 and 
ts-112. Studies have identified many genes highly expressed in hESCs to be upregulated 
in cancer cells (20). For this reason, ts-2 and ts-112 were chosen for our studies. Prior 
work in our laboratory showed that when t-2 and ts-112 are inhibited in MCF10CA1a 
cells, there is a decrease in growth, an increase in death, an increase in cell doubling time, 
and an increase in cell motility. Most recently, members of the Stein/Lian laboratory have 
reported that ts-112 is selectively responsive to runt-related transcription factor 1 
(RUNX1), a tumor suppressive transcription factor in mammary cells. In a recent 
publication, it was reported that ts-112 and RUNX1 are anticorrelated, shown through 
studies using both a normal model with MCF10A cells and a cancer model using 
MCF10CA1a cells. When RUNX1 is overexpressed in MCF10CA1a cells, ts-112 is 
downregulated (27).  Combined, these data suggest that ts-112 may be oncogenic.  
1.9 Hypothesis, Specific Aims and Project Overview 
Here, our long-term goal in characterizing this novel class of small non-coding 
RNA, tRNA-derived small RNA, is to understand further the molecular mechanisms of 
breast cancer initiation, progression, and metastasis. This knowledge could introduce a 
potential target for treatment of patients with aggressive breast cancer, in the effort of 
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increasing overall survival rates in patients with this disease. The overall objective of this 
study is to continue to examine the role of ts-2 and ts-112 in breast cancer through loss-
of-function and gain-of-function experiments. Our central hypothesis is that ts-2 and ts-
112 regulate cell growth, death, migration, and invasive ability to promote aggressive 
breast cancer disease progression. The rationale for this project is the unmet need to 
improve the survival rate in women diagnosed with stage IV breast cancer by discovering 
new treatment approaches. While stage I-III breast cancers have a 85-99% overall 5-year 
survival rate, stage IV breast cancer 5-year survival rate is only 27% and has not 
significantly improved in the last 20 years (1, 8).  
Aim 1 of the project is to identify the functions of ts-2 and ts-112 in aggressive 
breast cancer. To improve the rigor of this project and to further assess the role of ts-2 
and ts-112 in the metastatic MCF10CA1a cell line, we will compare different custom ts-2 
and ts-112 inhibitors with unique mechanisms of action. We will use cell proliferation 
(CCK-8) to validate preliminary cell counts over a 72-hour time course of tsRNA 
inhibition. In addition, we will test cell migration and invasion using a trans-well assay, 
to support our preliminary findings observed from a scratch assay.  
Aim 2 is to determine the ability of ts-2 and ts-112 to promote breast cancer 
characteristics in the normal mammary epithelium. We will assess cell growth, cell 
death, and the migratory abilities of MCF10A cells that have been transfected with 
mimics to overexpress ts-2 and ts-112. This approach will allow us to investigate the role 
of tsRNA molecules in promoting breast cancer phenotypes. These tests will be done 
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using the same assays as described in the ts-2 and ts-112 inhibited MCF10CA1a model 
(Aim 1).  
The work done to complete this project showed that ts-112 promotes cell 
proliferation. In assays using MCF10CA1a cells, ts-112 inhibited populations had a 
decrease in growth compared to control groups. In assays using MCF10A cells, the ts-
112 overexpressed populations had an increase in growth compared to the control groups. 
This finding is supportive of our central hypothesis and identifies ts-112 as a potential 
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CHAPTER 2: MATERIALS AND METHODS 
2.1: Cells 
The cell lines used in these studies include the normal-like breast epithelial cell line, 
MCF10A, and an aggressive breast cancer cell line, MCF10CA1a, derived from RAS-
transformed MCF10A cells. Both cell lines were grown and maintained in base media 
containing 50% DMEM and 50% F12 with L-glutamine (Corning, Thermo Fisher 
Scientific). Additional nutrients added to make complete media for MCF10A cells as 
volume/volume percentage: 5% horse serum (Gibco, Thermo Fisher Scientific), 1% 
penicillin G (100 units/mL) and streptomycin (100 μg/mL; Gibco, Thermo Fisher 
Scientific), 1% L-glutamine (Thermo Fisher Scientific), 0.1% human insulin (10 μg/mL 
final; Sigma-Aldrich), 0.02% human epidermal growth factor (20ng/mL final; 
PeproTech), 0.01% cholera toxin (100ng/mL final; Sigma-Aldrich), and 0.05% 
hydrocortisone (0.5 μg/mL final; Sigma-Aldrich). Additional nutrients added to the 
MCF10CA1a complete media as volume/volume percentage: 5% horse serum (Gibco 
Thermo Fisher Scientific) and 1% penicillin G (100 units/mL) and streptomycin (100 
μg/mL; Gibco, Thermo Fisher Scientific). Stock cells were maintained in 100 mm plastic 
tissue culture treated dishes (Corning, Thermo Fisher Scientific) at densities ranging from 
0.5x106 – 10x106 and 10 mL of media was renewed every 1-2 days. 
2.2: Inhibitors 
• Custom miRIDIAN hairpin inhibitors of ts-2 and ts-112 and a negative control 
inhibitor were purchased from Dharmacon (Horizon Discovery). 
o Sequences:  
▪ ts-2: 5’ – UGCAGCACGCCCUCCCAUUUUGGUG – 3’ 
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▪ ts-112: 5’ - CUCGGCUUUCCCUGCUAACUGGGCUUU - 3’  
▪ Negative Control:  5’ – UCACAACCUCCUAGAAAGAGUAGA 
– 3’  
 
• Single stranded mirVana miRNA oligonucleotides designed to bind and inhibit ts-
2 and ts-112 as well as a negative control inhibitor were purchased from Ambion 
(Invitrogen, Thermo Fisher Scientific). 
o Sequences:  
▪ Ts-2: 5’ – AAAUGGGAGGGCGUGc – 3’ 
▪ Ts-112: 5’ - AGCCCAGUUAGCAGGGAAAGCCGAGTT - 3’ 
▪ Negative Control: mirVana™ miRNA Inhibitor, Negative Control 
#1 
 
• Complexes were purchased from Qiagen, made to specifically inhibit ts-2 and ts-
112.  
o Sequence:  
▪ Ts-2: 5’ – AAATGGGAGGGCGTG – 3’ 
▪ Ts-112: 5’ – AGTTAGCAGGGAAAGCCGA – 3’ 




Custom mirVana miRNA mimics of ts-2 and ts-112 that are small, chemically modified 
double-stranded RNA molecules were purchased from Ambion (Invitrogen, Thermo 
Fisher Scientific).  
Sequences:  
Ts-2: 5’ – AUGGGAGGGCGUGCTT – 3’  
Ts-112: 5’ - AGCCCAGUUAGCAGGGAAAGCCGAGTT - 3’ 
Negative Control: mirVana™ miRNA Mimic, Negative Control #1 
 
2.4 Transfection 
Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific) was used as the transfection 
reagent for all transfections throughout this project. Cells were plated 24 hours prior to 
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transfection, which allowed time for cells to adhere to the plate and grow to be 70-90% 
confluent at the time of transfection. Conditions for 6-well plates (CytoOne Multiple 
Well Plates, USA Scientific) were 7.5 µL mimic/inhibitor, 5 µL P3000 reagent, and 7.5 
µL of Lipofectamine 3000 reagent. Conditions for 100mm dish (Corning, Thermo Fisher 
Scientific) were 25 µL mimic/inhibitor, 28 µL P3000 reagent, and 43 µL of 
Lipofectamine 3000 reagent. Prior to adding to cells, Lipofectamine 3000 reagent was 
combined with base DMEM/F-12 50/50 incomplete media (Corning, Thermo Fisher 
Scientific) and mixed well. A second master mix of mimic/inhibitor and P3000 reagent 
was made in base DMEM/F-12 50/50 incomplete media. The two master mixes were 
combined in a 1:1 ratio and incubated for 20 minutes to allow nucleic acid/lipofectamine 
complexes to form. An appropriate volume of transfection complexes (XX for 6WP, XX 
for 100mm) were added to pre-plated adhered cells in complete media and incubated at 
37°C for desired transfection time period (4 or 24 hours). 
2.5: Growth Curves 
5x106 viable MCF10CA1a cells, based on Trypan blue exclusion (Invitrogen, Thermo 
Fisher Scientific) count, were plated in 100 mm plastic tissue culture treated dishes 
(Corning, Thermo Fisher Scientific) with 10 mL complete media and allowed to adhere to 
the dish and grow for 24 hours. Cells were transfected with 50 nM inhibitor (Dharmacon, 
Horizon Discovery) or 25 nM inhibitor (Ambion, Invitrogen, Thermo Fisher Scientific) 
using Lipofectamine 3000 for 24 hours. Parallel controls included mock treatment (no 
nucleic acid) and appropriate negative control inhibitor. After incubation, cells of each 
condition were plated into wells of a 6-well plate (CytoOne Multiple Well Plates, USA 
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Scientific) at 5x104 cells/well with 2 mL complete media in triplicate wells. Cell counts 
were determined using trypan blue exclusion (10 µL cells in media and 10 µL trypan 
blue) (Invitrogen, Thermo Fisher Scientific) on a Countess II FL (Life Technologies, 
Thermo Fisher Scientific) automated cell counter 24, 48, and 72 hours after plating.  
2.6: Cell Counting Kit-8 
MCF10CA1a cells were plated in a single well of a 6-well plate (CytoOne Multiple Well 
Plates, USA Scientific) at viable cell counts of 0.5x106 and allowed time (24 hours) to 
adhere to the plate and grow. Cells were transfected with 50 nM inhibitor (Dharmacon, 
Horizon Discovery) or 25 nM inhibitor (Ambion, Invitrogen, Thermo Fisher Scientific) 
using Lipofectamine 3000 for 4 hours. Parallel controls included mock treatment (no 
nucleic acid) and appropriate negative control inhibitor. The same procedure was 
performed for MCF10A cells using 25 nM mimics (Ambion, Invitrogen, Thermo Fisher 
Scientific). After the 4 hour incubation with transfection complexes, cells of each 
condition were plated in triplicates per condition in 96-well flat bottom plates (Costar, 
Corning, Thermo Fisher Scientific) at 5,000 cells in 100 µL of complete media. 10 µL of 
WST-8 tetrazolium salt (Abcam) was added to each well at appropriate time points (0, 
24, 48, 72 hours post-plating) and allowed to incubate for 3 hours. Cell viability was 
assessed using a Victor X4 (Perkin Elmer, Inc.) plate reader at an absorbance of 450 nm. 
Background (complete media + WST-8) was subtracted from absorbance readings in 




2.7: Flow Cytometry 
For cell cycle analysis, cells were harvested after 24-hour transfection with Dharmacon 
inhibitors and fixed in 100% cold EtOH, added dropwise, mixing well. A Cell Cycle Kit 
(BD Biosciences) was used by manufacturer’s instructions. Unstained and stained cells 
were profiled in the UVM Flow Core by Roxanna Del Rio Guerra. Cell cycle was 
modeled in FlowJo (Treestar) and Modfit (Verity Software) based on DNA content. 
2.8: Trans-well Assay 
MCF10A and MCF10CA1a cells were plated in 100 mm plastic tissue culture treated 
dishes (Corning, Thermo Fisher Scientific) 24 hours prior to transfection with 25 nM of 
mimic or inhibitor (Ambion, Invitrogen, Thermo Fisher Scientific) for 4 hours. 
Corning™ BioCoat™ Matrigel™ Invasion Chambers with or without a GFR Matrigel 
matrix coating (Thermo Fisher Scientific) were warmed to room temperature and 
rehydrated using warm, serum-free media and incubated at 37°C for 2 hours. After 4 
hours of transfection incubation, 50,000 cells were plated into invasion chambers (lined 
with GFR Matrigel) or migration chambers (control, no lining) containing serum-free 
media. Cells were allowed to invade/migrate through the gel chambers and into full-
serum media for 24 hours. Cells were fixed with methanol and stained with crystal violet 
stain for imaging on an inverted microscope. 
2.9: RNA Isolation 
To prepare for isolation of RNA after transfection with mimic or inhibitors, cells were 
lysed with QIAzol reagent and transferred into a 1.5 mL tube (Eppendorf). Chloroform 
was added to separate the RNA layer from other cellular components. Ethanol was added 
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and samples were passed through a spin column (Qiagen) for filtration. After addition of 
various buffers, columns were spun, and flow through was discarded per manufacturer 
guidelines (miRNeasy Mini Kit, Qiagen), including a DNase digestion and isolated RNA 
was stored at -80°C. 
2.10: cDNA Synthesis 
RNA samples were thawed and 1.5 µL of each sample was analyzed on a Nanodrop 2000 
Spectrophotometer (Thermo Fisher Scientific), which quantified the RNA concentration 
for each sample. Samples were diluted using RNase free water to a uniform concentration 
of 500 ng/µL. Reverse transcriptase (RT) master mix was prepared using 4 µL of 5X 
miScript HiSpec buffer (Qiagen), 2 µL of 10X miScript Nucleics mix (Qiagen), 2 µL of 
RNase-free water, and 2 µL of miScript reverse transcriptase mix per reaction (Qiagen). 
Samples, including a sample without reverse transcriptase master mix, were combined 
with this RT mastermix, briefly vortexed and spun for mixing, and cDNA was 
synthesized using a C1000 touch Thermal Cycler machine (Bio-Rad Laboratories) using 
the following protocol: 1 cycle of 60 minutes at 37°C, 5 minutes at 95°C, and held at 4°C 
until storage at -20°C.  
2.11: Primer Sequences 
Specific forward primers and the Universal Reverse Primer used for qPCR analysis were 
purchased from Invitrogen (Thermo Fisher Scientific).  
▪ Sequences:  
o U6 (control): 5’ – AGCCAAATTCGTGAAGCGTTCCATATT – 3’ 
o Ts-2: 5’ – TGCAGCACGCCCTCCCATTTT – 3’  





2.12: Quantitative Polymerase Chain Reaction (qPCR) 
qPCR was performed using miScript qPCR with QuantiTect SYBR Green (Qiagen). Each 
well of a 96-well flat bottom plate (Costar, Corning, Thermo Fisher Scientific) contained: 
10 µL of 2x QuantiTect SYBR green PCR master mix, 2 µL of 10 uM miRNA/tsRNA 
specific forward primer, 2 µL of 10 uM Universal Reverse primer, 2 µL of diluted 
cDNA, and 4 µL of RNase-free water.  The 96-well flat bottom plate (Costar, Corning, 
Thermo Fisher Scientific) was loaded into and run on a ViiA7 qPCR machine using the 
following protocol: 15 minutes at 95°C, followed by 40 cycles of 15 seconds at 94°C 
(melt), 30 seconds at 55°C (anneal), and 30 second at 70°C (elongate), followed by a 
melt curve.  
2.13: Statistics 
Excel (Microsoft) and Prism 8 (GraphPad) were used for data entry and visualization. 
Statistics were calculated using Excel (Microsoft) to generate two tailed, homoscedastic 
t-tests of mock or negative control versus the test populations. The p-values to identify 
statistical significance is described within each figure legend. Error bars are made using 






CHAPTER 3: RESULTS 
Aim 1: Identify the functions of ts-2 or ts-112 in aggressive breast cancer. 
To improve the rigor of this project and to further assess the role of ts-2 or ts-112 
in the metastatic MCF10CA1a cell line, we compared custom ts-2 or ts-112 inhibitors 
with unique mechanisms of action that were purchased from three different companies. 
We monitored cell proliferation over a 72-hour time course (trypan blue exclusion, CCK-
8) to validate preliminary cell count data suggesting tsRNA inhibition slows cell growth 
rate over time. Changes in cell cycle distribution were observed using flow cytometry.  In 
addition, we tested cell migration and invasion using a trans-well assay to support 
preliminary scratch assay findings that ts-112 inhibition increases wound healing.  
3.1: Dharmacon miRIDIAN hairpin inhibitors against ts-2 or ts-112 reduce 
MCF10CA1a cell number over time 
 To evaluate how ts-2 or ts-112 are involved in regulating cancer cell growth, 
MCF10CA1a cells were transfected with Dharmacon miRIDIAN hairpin inhibitors using 
the Lipofectamine 3000 transfection reagent. The miRIDIAN inhibitor is composed of 
modified RNA with a single-stranded RNA-targeting region bookended by hairpins for 
stability. miRIDIAN inhibitors (50 nM) with complementary sequences to ts-2 or ts-112, 
or a negative control inhibitor tagged with fluorescent dye to confirm transfection 
efficiency, were transfected into 5x106 viable MCF10CA1a cells. A mock control with no 
nucleic acid was included. After 24-hours, cells were plated at 5x104 cells/well in 
triplicate in 6-well plates and then counted on a Countess II using trypan blue exclusion 
24, 48, and 72 hours after plating to identify live and dead cells.  
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 Phase-bright, trypan blue negative (viable) cell counts from three independent 
experiments were plotted over time (Figure 3.1). At 72 hours, the number of 
MCF10CA1a cells transfected with either ts-2 or ts-112 inhibitor were reduced as 
compared to mock and negative control. On average, inhibition of ts-112 or ts-2 resulted 
in an approximate 10% or 15% decrease in population size, respectively, suggesting a 
reduction in growth rate. These differences did not reach statistical significance (Tables 
3.1-3.3). However, the ts-112 inhibited population showed a suggestive decrease in cell 
count (p = 0.093) at 24 hours when compared to either the mock or negative control 
cells/groups (see † in Tables 3.1-3.3). Further, MCF10CA1a cells with ts-2 or ts-112 
inhibited, shown in blue and red respectively on the graph (Figure 3.1), have an apparent 
decrease in growth rate over time between 48 and 72 hours. Although this decrease is not 
statistically significant, a shallower slope of the line on the figure suggests that there is a 
decrease in population doubling time. Combined, these data suggest that ts-2 or ts-112 
could be involved in promoting cell proliferation in aggressive breast cancer. 
3.2: Inhibitors of ts-112 may decrease MCF10CA1a cell proliferation rate 
 To confirm our observation that ts-2 or ts-112 inhibition leads to slower growth, 
we performed a different cell proliferation assay (CCK-8) with Dharmacon miRIDIAN 
inhibitors and introduced a new set of tsRNA inhibitors, Ambion mirVana antisense 
oligonucleotides. Cell proliferation was observed using absorbance readings following a 
Cell Counting Kit-8 assay.  MCF10CA1a cell groups for this experiment were transfected 
using Lipofectaine 3000 for 4 hours in attempt to observe the early decrease in growth 
seen in the Dharmacon miRIDIAN Inhibitor Growth Curves  
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Figure 3.1:  Ts-2 or ts-112 inhibition with miRIDIAN inhibitors may lead to slower 
growth of MCF10CA1a cells. 
Live cell (phase bright, trypan blue excluding) numbers were determined at 24-hour 
intervals for 72 hours following ts-2 or ts-112 inhibition using Dharmacon miRIDIAN 
custom hairpin inhibitors. Cell count of the ts-112 inhibited population was suggestive (p 
< 0.1) to be decreased as compared to the mock population at 24 hours after plating. The 
slope of both the ts-2 or ts-112 populations suggest slowed growth over time compared to 
the control populations between the 48- and 72-hour time points, although the change 
was not significant compared to control populations.  Error bars represent the SEM of 3 




Table 3.1: Normalized Experimental Mean Live MCF10CA1a Cell Counts 
Time 
(Hours) 
Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 50,000 50,000 50,000 50,000 50,000 50,000 
24 58,633 80,233 40,233 41,033 64,500 63,133 
48 179,667 209,000 198,667 199,333 148,333 145,000 
72 750,667 731,000 713,333 664,667 512,000 980,333 
Cell counts were generated using trypan blue exclusion on a Life Technologies Countess 
II FL machine 24, 48, and 72 hours from plating 50,000 live cells. Reported cell count 
values are experiment mean of triplicate wells. 
Table 3.2: Mean and Standard Error of the Mean (SEM) of 3 Experiments 
Time 
(Hours) 
Mock Negative Control 
Mean SEM Mean SEM 
0 50,000 0 50,000 0 
24 59,700 11,559 56,222 7,605 
48 195,778 8,590 164,222 17,582 
72 731,667 10,782 719,000 137,899 
Mean and SEM of 3 independent experiments performed in triplicate.  
Table 3.3: Two-tailed, homoscedastic t-test  




Ts-2 Inhibitor Ts-112 Inhibitor 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 50,000 50,000 50,000 50,000 50,000 50,000 
24 82,100 54,733 56,100 41,067 21,500 31,867 
48 256,000 193,667 167,000 144,567 244,333 200,000 
72 678,333 408,333 614,000 375,333 587,000 846,667 
Time 
(Hours) 
Ts-2 Inhibitor Ts-112 Inhibitor 
Mean SEM Mean SEM 
0 50,000 0 50,000 0 
24 64,311 8,903 31,478 5,652 
48 205,556 26,371 196,300 28,859 


















24 0.814 0.768 0.093† 0.528 0.059† 
48 0.182 0.74 0.987 0.262 0.396 
72 0.931 0.115 0.400 0.396 0.582 
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performed previously. First, the absorbance at 450 nm of mock (no nucleic acid) and 
negative control (tagged with fluorescent dye to confirm transfection efficiency) groups 
were compared to the populations of cells transfected with 50 nM Dharmacon 
miRIDIAN, double stranded, complementary inhibitors with hairpin bookends of ts-2 or 
ts-112. After transfection incubation, cells were plated at 5x103 cells/well in 96-well 
plates in triplicate per condition. At appropriate time points after plating (0-hours, 24-
hours, 48-hours, and 72-hours), WST-8 tetrazolium salt reagent was added for 3 hours 
and cell proliferation was assessed on a Victor X4 plate reader at absorbance 450 nm. 
Numbers reported below (Tables 3.4-3.6) have been normalized to eliminate background 
and represent averages of triplicate wells per experiment. Mean and SEM have been 
reported and used to generate the graph. A two-tailed, homoscedastic t-test suggests that 
the ts-112 inhibited population has a slower proliferation rate compared to the mock 
population (p < 0.1) at the 72-hour time point (Figure 3.2A). While the mean absorbance 
value of the 72-hour time point for the ts-112 inhibited population is 1.289, the other 3 
cell populations have an absorbance value of around 1.4 for that time point. This result 
agrees with our hypothesis and with the trypan blue exclusion result, further showing that 
ts-112 promotes cell growth. 
In attempt to increase confidence in our findings, MCF10CA1a cells were 
transfected, using Lipofectamine 3000, with 25 nM Ambion mirVana inhibitors for the 
CCK-8 proliferation assay. Here 25 nM inhibitor was used instead of 50 nM due to a 

































































Figure 3.2: Inhibition of ts-112 may lead to decrease in MCF10CA1a cell 
proliferation. 
A. CCK-8 assay for cell proliferation is performed by measuring absorbance (OD 450 
nm) of MCF10CA1a cells following 4-hour inhibition of ts-2 or ts-112. Absorbance 
values are representative of viable cells. A suggestive (p < 0.1) reduction in OD 450 nm 
was observed in the ts-112 inhibited population at 72-hours after plating as compared to 
the mock population. Error bars represent the SEM of 3 independent experiments 
performed in triplicate. † p < 0.1. B. CCK-8 assay for cell proliferation is performed by 
measuring absorbance (OD 450 nm) of MCF10CA1a cells following 4-hour inhibition of 
ts-2 or ts-112. Absorbance values are representative of viable cells. At both 48- and 72-
hours following a 4-hour transfection with inhibitor Viable cell count is decreased 
significantly (p < 0.05). Error bars represent the SEM of 3 independent experiments 






Table 3.4: Absorbance (OD 450 nm) 
Time 
(Hours) 
Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 0.046 0.132 0.105 0.121 0.071 0.039 
24 0.208 0.388 0.521 0.319 0.312 0.211 
48 0.476 1.056 1.408 0.747 0.899 0.543 
72 1.315 1.438 1.391 1.478 1.443 1.293 
Absorbance values read at OD 450 nm have been normalized to wells with only media 
and WST-8 to eliminate background. Values reported represent the background 
corrected mean of triplicate wells per experiment. 
Table 3.5: Mean and Standard Error of the Mean of 3 Experiments 
Time 
(Hours) 
Mock Negative Control 
Mean SEM Mean SEM 
0 0.094 0.025 0.077 0.024 
24 0.372 0.091 0.281 0.035 
48 0.980 0.272 0.730 0.103 
72 1.381 0.036 1.405 0.057 
Mean and SEM of 3 independent experiments performed in triplicates. 
Table 3.6: Two-tailed, homoscedastic t-test  
† p < 0.1  
Time 
(Hours) 
Ts-2 Inhibitor Ts-112 Inhibitor 
 Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 0.092 0.119 0.087 0.126 0.036 0.187 
24 0.251 0.513 0.361 0.282 0.237 0.645 
48 0.608 1.237 0.889 0.643 0.582 1.499 
72 1.381 1.517 1.379 1.282 1.299 1.287 
Time 
(Hours) 
Ts-2 Inhibitor Ts-112 Inhibitor 
Mean SEM Mean SEM 
0 0.099 0.010 0.116 0.044 
24 0.375 0.076 0.388 0.129 
48 0.911 0.182 0.908 0.296 



















0 0.645 0.863 0.687 0.436 0.475 
24 0.399 0.983 0.926 0.322 0.467 
48 0.438 0.844 0.867 0.434 0.600 
72 0.746 0.488 0.064† 0.787 0.113 
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Table 3.7: Absorbance (OD 450 nm) 
Time 
(Hours) 
Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 0.100 0.053 0.138 0.098 0.080 0.069 
24 0.290 0.254 0.547 0.258 0.356 0.320 
48 0.809 0.843 1.291 0.728 1.107 0.922 
72 1.479 1.432 1.374 1.469 1.494 1.532 
Absorbance values read at OD 450 nm have been normalized values to wells with only 
media and WST-8 to eliminate background. Values reported represent the background 
corrected mean of triplicate wells per experiment. 
Table 3.8: Mean and Standard Error of the Mean of 3 Experiments 
Mean and SEM of 3 independent experiments performed in triplicate. 
Table 3.9: Two-tailed, homoscedastic t-test  




Ts-2 Inhibitor Ts-112 Inhibitor 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 0.112 0.073 0.037 0.026 0.039 0.034 
24 0.235 0.306 0.241 0.122 0.215 0.164 
48 0.807 0.956 0.709 0.488 0.626 0.381 
72 1.481 1.494 1.445 1.049 1.257 0.975 
Time 
(Hours) 
Mock Negative Control 
Mean SEM Mean SEM 
0 0.097 0.025 0.082 0.008 
24 0.364 0.092 0.311 0.029 
48 0.981 0.155 0.919 0.109 
72 1.428 0.030 1.498 0.018 
Time 
(Hours) 
Ts-2 Inhibitor Ts-112 Inhibitor 
Mean SEM Mean SEM 
0 0.074 0.022 0.033 0.004 
24 0.260 0.023 0,167 0.027 
48 0.824 0.072 0.498 0.071 




















0 0.603 0.521 0.062† 0.738 0.006** 
24 0.617 0.339 0.110 0.238 0.021* 
48 0.761 0.411 0.047* 0.508 0.032* 
72 0.120 0.253 0.020* 0.347 0.009** 
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cells were transfected for 4-hours with mock (no nucleic acid), negative control, single 
stranded oligonucleotide inhibitors of ts-2 or ts-112. Following transfection incubation, 
cells were plated at 5,000 cells/well in 96-well plates. At appropriate time points after 
plating (at 24-hour increments from 0-72 hours), WST-8 reagent was added and 
absorbance was read 3 hours later at 450 nm.  
 Using Ambion mirVana inhibitors, cell proliferation of the ts-112 inhibited 
population of cells decreased about 50% compared to the mock population at the 48- and 
72-hour time points (Tables 3.7-3.9, Figure 3.2B). Again, a potential for seeing different 
results for the same experiment (CCK-8) within the same cell line could be explained by 
the fact that the Dharmacon miRIDIAN inhibitors and the Ambion mirVana inhibitors are 
working to inhibit the tsRNA molecules of interest by different mechanisms. For the 
CCK-8 assays, both inhibitors reflected a decrease in cell proliferation in the ts-112 
inhibited population when compared to the mock, with the Ambion mirVana inhibitor 
assay showing statistical decrease in cell proliferation. These results were seen using half 
the concentration of Ambion mirVana inhibitors than was used for the Dharmacon 
miRIDIAN inhibitor assays. 
3.3: Ambion mirVana antisense oligonucleotide inhibitors against ts-2 or ts-112 do 
not change MCF10CA1a cell counts over time 
To determine if 25 nM Ambion mirVana inhibitor could replicate the results seen 
following a trypan blue exclusion growth curve with 50 nM Dharmacon miRIDIAN 
inhibitors, we performed the experiment with Ambion mirVana inhibitors of ts-2 or ts-
112. Control groups include mock (no nucleic acid) and negative control. Single-stranded 
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antisense oligonucleotide inhibitors against ts-2 or ts-112 were transfected at 25 nM 
concentration into the MCF10CA1a cells using the Lipofectamine 3000 transfection 
reagent. The experiment was performed as with the Dharmacon miRIDIAN inhibitors 
described above. While the miRIDIAN inhibitors showed a potential decrease in 
population growth over time of the tsRNA inhibited populations, the mirVana inhibitors 
showed no difference between test groups and control groups (Figure 3.3). At each time 
point throughout the experiment, the mock, negative control, ts-2 inhibited, and ts-112 
inhibited populations were growing at the same rate (Table 3.10-3.12). Varying results 
between the two inhibitor types could be explained by the fact that the two inhibitors are 
working different ways. While the miRIDIAN inhibitors sequester the tsRNAs using 
hairpin loops, the mirVana inhibitors are oligonucleotides designed to bind to the tsRNAs 
of interest.  
3.4: Inhibition of ts-2 or ts-112 in MCF10CA1a cells increased percent of population 
in S phase of the cell cycle 
 To further investigate changes in MCF10CA1a cell growth following ts-2 or ts-
112 inhibition, we performed cell cycle analysis after a 24-hour transfection with 50nM 
Dharmacon miRIDIAN inhibitors using flow cytometry. Here, we observed an increase 
in cells in S phase, and a decrease in G1 phase in the ts-2 or ts-112 inhibited populations  
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Figure 3.3: Inhibition of ts-2 or ts-112 in MCF10CA1a cells with mirVana inhibitors 
does not change cell growth rate. 
Live cell (phase bright, trypan blue excluding) numbers were determined at 24-hour 
intervals for 72 hours following ts-2 or ts-112 inhibition using Ambion mirVana single-
stranded oligonucleotide inhibitors. Ts-2 or ts-112 inhibited populations appear to have 
an increase in growth rate, especially between 48- and 72-hours after a 24-hour 
transfection, although there are no significant differences between control and test 

























Table 3.10: Normalized Experimental Mean Live MCF10CA1a Cell Counts 
Time 
(Hours) 
Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 50,000 50,000 50,000 50,000 50,000 50,000 
24 37,700 67,233 34,800 37,767 37,533 24,433 
48 125,333 120,633 99,333 86,300 187,667 106,433 
72 635,333 512,333 545,500 623,667 408,287 658,666 
Cell counts were generated using trypan blue exclusion on a Life Technologies Countess 
II FL machine 24, 48, and 72 hours from plating 50,000 live cells. Reported cell count 
values are the mean of triplicate wells.  
Table 3.11: Mean and Standard Error of the Mean of 3 experiments  
Time 
(Hours) 
M ock Negative Control 
Mean SEM Mean SEM 
0 50,000 0 50,000 0 
24 46,578 10,362 33,244 4,406 
48 115,100 7,999 126,800 30,983 
72 564,389 36,742 563,540 78,281 
Mean and SEM of 3 independent experiments performed in triplicate. 



















24 0.302 0.438 0.368 0.606 0.923 
48 0.733 0.589 0.768 0.788 0.970 




Ts-2 Inhibitor Ts-112 Inhibitor 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 50,000 50,000 50,000 50,000 50,000 50,000 
24 28,933 44,967 36,566 37,733 43,366 21,100 
48 97,433 236,667 94,800 97,833 214,000 74,866 
72 692,000 534,333 617,666 764,333 606,000 664,666 
Time 
(Hours) 
Ts-2 Inhibitor Ts-112 Inhibitor 
Mean SEM Mean SEM 
0 50,000 0 50000 0 
24 36,822 4,630 34,067 6,684 
48 142,967 46,856 128,900 43,063 
72 614,667 45,539 678,333 46,215 
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when compared to the mock and negative control populations (Figure 3.4, Tables 3.13-
3.15). Since the S phase of the cell cycle is defined by DNA synthesis, the increase in the 
percent of cells in the population being in this phase of the cell cycle could help explain 
why we saw an increase in cell number in the trypan blue experiments and an increase in 
cell proliferation in the CCK-8 assays. An increase in S phase may indicate that the cells 
are blocked in S phase. 
3.5: Inhibition of ts-2 or ts-112 in MCF10CA1a cells does not significantly affect cell 
death rates 
 Cancer cells have the inherent ability to avoid death signals and evade apoptosis. 
To assess whether ts-2 or ts-112 are regulators of this characteristic of cancer, we used 
the cell death percentages read by the Countess II during the trypan blue exclusion 
growth curves. No more than 5% cell death over the 72- hour time course was observed 
in any experimental condition (Figure 3.5, Table 3.16-3.18). It is common to see cell 
death ≤ 5% in MCF10CA1a cells, even in a stock plate growing with no transfection and 
ample nutrients. Thus, there is no effect on cell death when ts-2 or ts-112 are inhibited 
using miRIDIAN inhibitors in MCF10CA1a cells. We saw a parallel result in a trypan 
blue exclusion growth curve after treatment with Ambion mirVana inhibitors (data not 
shown). Further, in an ApoTox-Glo cell death assay using Annexin V, no population of 
cells -- control, ts-2 inhibited, or ts-112 inhibited -- had more cell death than another. 
There was no increase in the sub-G1 phase when we performed flow cytometry analysis 




Figure 3.4: There is an apparent increase in S phase and decrease in G1 phase 
following MCF10CA1a inhibition of ts-2 or ts-112 with Dharmacon miRIDIAN 
inhibitors. Flow cytometry analysis was performed following a 24-hour Dharmacon 
miRIDIAN inhibition of ts-2 or ts-112 in MCF10CA1a cells. Although it does not reach 
statistical significance, there is an apparent decrease in S phase, and a decrease in GI 
phase of the cell populations with either ts-2 or ts-112 inhibited compared to the mock 
population. A. Stacked bar graph of population percentage in each phase of the cell cycle. 
B-E. Pie charts including average population percentages in each phase of the cell cycle. 
F-I. Histograms with X-axis of 7-AAD-A overlaid with Dean-Jett-Fox model. 
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Table 3.13: Population Percentage by Stage  
Phase Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
G1 77.95% 73.99% 72.83% 76.59% 71.62% 69.63% 
S 17.78% 18.60% 8.94% 19.59% 19.33% 8.48% 
G2 4.27% 7.40% 18.23% 3.82% 9.05% 21.88% 
Percentages normalized to 100%  
Table 3.14: Mean and Standard Error of the Mean of 3 experiments  
Phase Mock Negative Control 
Mean SEM Mean SEM 
G1 74.93% 1.55 72.62% 2.07 
S 15.12% 3.09 15.80% 3.66 
G2 9.96% 4.23 11.58% 5.37 
Mean and SEM of 3 independent experiments performed in triplicate. 
Table 3.15: Two-tailed, homoscedastic t-test  
















G1 0.422 0.145 0.187 0.604 0.604 
S 0.892 0.466 0.386 0.578 0.578 







Phase Ts-2 Inhibitor Ts-112 Inhibitor 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
G1 73.86% 70.30% 69.54% 74.31% 69.94% 62.57% 
S 21.61% 22.91% 11.99% 13.60% 22.57% 21.34% 
G2 4.53% 6.79% 18.47% 12.08% 7.49% 16.10% 
Phase Ts-2 Inhibitor Ts-112 Inhibitor 
Mean SEM Mean SEM 
G1 71.23% 1.33 68.94% 3.43 
S 18.84% 3.45 19.17% 2.81 
G2 9.93% 4.32 11.89% 2.49 
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Figure 3.5: Inhibition of ts-2 or ts-112 with miRIDIAN inhibitors has no effect on 
cell death. 
Cell death percentages were reported by the Countess II machine during a 72-hour trypan 
blue exclusion growth curves of MCF10CA1a cells following 24 hour inhibition with 
Dharmacon miRIDIAN inhibitors. Death percentages from 3 independent experiments 
averaged less than 5% throughout each population of cells. There is no significant effect 






Table 3.16: Normalized Experimental Mean Dead MCF10CA1a Cell Percentages 
Time 
(Hours) 
Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 
24 0.00% 16.00%× 1.33% 3.33% 11.33%× 3.67% 
48 0.04% 0.03% 0.02% 4.00% 4.00% 2.00% 
72 3.00% 2.00% 2.66% 1.33% 2.33% 1.33% 
Cell death percentages were generated using trypan blue exclusion on a Life 
Technologies Countess II FL machine 24, 48, and 72 hours from plating 50,000 live cells. 
Reported cell count values are experiment mean of triplicate wells. Cells marked with × 
were omitted outliers. 
Table 3.17: Mean and Standard Error of the Mean (SEM) of 3 Experiments 
Time 
(Hours) 
Mock Negative Control 
Mean SEM Mean SEM 
0 0.00% 0.00 0.00% 0.00 
24 0.67% 0.94 3.50% 0.23 
48 0.03% 0.01 3.33% 1.15 
72 2.56% 0.51 1.67% 0.58 
Mean and SEM of 3 independent experiments performed in triplicate.  




Ts-2 Inhibitor Ts-112 Inhibitor 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
24 0.00% 21.33%× 0.04% 0.00% 56.67%× 2.67% 
48 4.67% 3.00% 2.67% 6.67% 3.00% 3.00% 
72 1.67% 3.00% 2.33% 0.50% 2.00% 2.67% 
Time 
(Hours) 
Ts-2 Inhibitor Ts-112 Inhibitor 
Mean SEM Mean SEM 
0 0.00% 0.00 0.00% 0.00 
24 0.02% 0.03 1.33% 1.89 
48 2.56% 2.35 4.22% 2.12 




















24 0.05 0.43 0.70 0.00 0.25 
48 0.01 0.14 0.03 0.64 0.56 
72 0.12 0.67 0.30 0.26 0.94 
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3.6: MCF10CA1a cell inhibition of ts-2 or ts-112 with Ambion mirVana inhibitors 
does not change cell migration 
 A characteristic of aggressive cancer is its ability to migrate to and invade 
surrounding tissue. After observing cell proliferation of MCF10CA1a cells with ts-2 or 
ts-112 inhibition, we focused on the migratory and invasive ability of these cells. Here, 
we expected ts-2 or ts-112 inhibited populations to migrate less than the mock 
populations, since our hypothesis is that these molecules promote cancer phenotypes. To 
assess the migratory ability of MCF10CA1a cells after inhibition of tsRNA molecules of 
interest, 25 nM Ambion mirVana inhibitors of ts-2 or ts-112 were transfected into the 
cells for 4 hours using Lipofectamine 3000. Cells (5x104 cells/well) in serum free media 
were plated into migration (control) chambers of a transwell plate and allowed to migrate 
through the membrane to the bottom chamber containing full media for 24 hours. At the 
appropriate time point, cells were fixed with ethanol and stained with crystal violet for 
imaging.  
 Our results were unexpected. To reiterate, if the central hypothesis that ts-2 or ts-
112 promote cancer phenotypes, inhibition either of these molecules would lead to a 
decrease in migration compared to the mock and negative control populations. Instead, all 
of our groups, including the ts-2 or ts-112 inhibited population groups did not show any 
migration (Figure 3.6). Images were taken on a inverted microscope at 3.5x to allow 
visualization of the entire well. If cells are migratory, they would appear more purple in 





Figure 3.6: Ts-2 or ts-112 inhibition in MCF10CA1a cells does not effect cell 
migration. 
Cell migration was assessed using control (no matrigel lining) inserts in a trans-well 
assay. Pictures depict the bottom of both the inserts (top column) and wells (bottom 
column) after allowing cell poplations to migrate for 24 hours. No cells migrated from 
the well inserts into the well bottoms, indicating no migration of MCF10CA1a, no matter 















Due to the shutdown of UVM laboratories, this experiment was only performed once (n = 
1). It is important to repeat this experiment in attempt to gain a better understanding of 
how manipulation of ts-2 or ts-112 levels in MCF10CA1a cells effects cell motility. 
These cells were fixed and stained with crystal violet, but perhaps an assay involving 
florescence would allow for better visualization of any potental migration occuring. 
Aim 2: Determine the ability of ts-2 or ts-112 to promote breast cancer development 
in the normal mammary epithelium 
We assessed cell growth, cell death, and the migratory abilities of MCF10A cells 
that have been transfected with mimics to overexpress ts-2 or ts-112. This approach 
allowed us to investigate the role of tsRNA molecules in promoting breast cancer 
phenotypes, in order to determine if tsRNAs are involved in breast cancer development or 
initiation. These experiments were done using the same assays performed in 
MCF10CA1a cells (Aim 1). 
3.7: Ambion mirVana mimic overexpression of ts-2 or ts-112 may increase growth 
rate of MCF10A cells 
 To further investigate the role of ts-2 or ts-112 in regulating cancer cell 
growth, normal-like breast epithelial MCF10A cells were transfected with tsRNA 
mimics. Ambion mirVana double-stranded RNA molecules designed to specifically 
overexpress ts-2 or ts-112 were transfected into the MCF10A cells using the 
Lipofectamine 3000 transfection reagent. These experiments were performed as 
described for tsRNA inhibition in MCF10CA1a cells. Control groups were a mock (no 
nucleic acid) and a negative control transfection. Test groups were transfected with 25 
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nM mimics of ts-2 or ts-112. Viable cells (5x106) were plated in 100 mm plastic tissue 
culture dishes and transfected with either mock, negative control, ts-2 mimic, or ts-112 
mimic for 24-hours. After transfection incubation, cells were plated in triplicate per 
condition at 5x104 cells/well in 6-well plates. Cells were counted 24, 48, and 72 hours 
after plating using trypan blue exclusion.  
 This experiment was performed in three independent experiments, in triplicate 
(n=3). We expected the results from this experiment to supplement the results from the 
growth curve experiments in Aim 1. There, MCF10CA1a inhibition of ts-2 or ts-112 led 
to decreased growth rate over time. Here, we expect MCF10A overexpression of ts-2 or 
ts-112 to have an increase in growth rate. Instead, there is no statistical difference 
between mock and ts-2 or ts-112 inhibited populations (Figure 3.7, Tables 3.19 – 3.21). 
Error bars are large due to inconsistencies between replicates, and results reflecting the 
expected increase in cell growth are likely if this experiment were repeated.  
 3.8: CCK-8 assay with Ambion mirVana mimics show an apparent increase 
in growth of the ts-2 or ts-112 overexpressed popuations 
Cell counting kit-8 (CCK-8) assay for cell proliferation was performed on 
MCF10A cells to allow for greater understanding of the role of ts-2 or ts-112 in breast 
cells. MCF101A cells were transfected, using Lipofectamine 3000, with 25 nM Ambion 
mirVana mimics.  Groups for this experiment were mock (no nucleic acid), negative 
control, or populations transfected with mimics of either ts-2 or ts-112 for 
overexpression. Transfection incubation lasted 4 hours and the experiment followed 
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Figure 3.7: Overexpression of ts-2 or ts-112 in MCF10A cells with mirVana mimics 
may decrease cell growth rate. 
Live cell (phase bright, trypan blue excluding) numbers were determined at 24-hour 
intervals for 72 hours following ts-2 or ts-112 overexpression using Ambion mirVana 
double-stranded oligonucleotide mimics. Ts-112 mimic populations appear to have a 
decrease in growth rate, especially between 48- and 72-hours after plating, although there 
are no significant differences between control and mimic populations. Error bars 






















Table 3.19: Live Cell Counts  
Time Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 50,000 50,000 50,000 50,000 50,000 50,000 
24 36,367 28,933 1,410 17,193 16,627 5,245 
48 182,333 141,000 38,333 134,967 97,967 179,333 
72 985,667 510,233 271,667 893,333 355,667 904,333 
Cell counts were generated using trypan blue exclusion on a Life Technologies Countess 
II FL machine 24, 48, and 72 hours from plating 50,000 live cells. Reported cell count 
values are experiment mean of triplicate wells.  
Table 3.20: Mean and Standard Error of the Mean  
Time 
(Hours) 
Mock Negative Control 
Mean SEM Mean SEM 
0 50,000 0 50,000 0 
24 22,237 10,632 13,022 3,892 
48 120,555 42,807 137,422 23,521 
72 589,189 209,861 717,778 181,083 
Mean and SEM of 3 independent experiments performed in triplicate. 

















24 0.461 0.667 0.233 0.799 0.299 
48 0.747 0.901 0.228 0.524 0.0560† 
72 0.667 0.431 0.640 0.573 0.366 
† p < 0.1 
   
Time 
(Hours) 
Ts-2 Mimic Ts-112 Mimic 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 50,000 50,000 50,000 50,000 50,000 50,000 
24 34,000 5,575 7,625 14,650 1,758 2,053 
48 88,850 91,733 161,667 70,450 78,200 4,985 
72 508,333 662,000 1,806,000 730,333 541,667 54,733 
Time 
(Hours) 
Ts-2 Mimic Ts-112 Mimic 
Mean SEM Mean SEM 
0 50,000 0 50,000 0 
24 15,733 9,152 6,154 4,249 
48 114,083 23,806 51,212 23,221 
72 992,111 409,355 442,244 201,265 
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the same methods as the CCK-8 assays performed in Aim 1. After transfection 
incubation, cells were plated at 5x103 cells/well density in 96-well plates in triplicate per 
condition. At appropriate time points after plating (0-hours, 24-hours, 48-hours, and 72-
hours), WST-8 tetrazolium salt reagent was added to each well for 3 hours and cell 
proliferation was assessed on a Victor X4 plate reader at absorbance 450 nm. Numbers 
reported below (Tables 3.22-3.24) have been normalized to eliminate background and 
represent averages of triplicate wells per experiment. Mean and SEM have been reported 
and used to generate the graph. Two tailed, homoscedastic t-tests were performed to 
generate statistical analysis of this data. Despite not reaching a statistical difference, the 
ts-2 or ts-112 overexpressed populations appear to have an increase in proliferation rate 
compared to the mock and negative control populations (Figure 3.8). At the 72-hour time 
point, the mean absorbance value of the mock population is 1.381 while the ts-2 or ts-112 
overexpressed absorbance values are 1.650 and 1.601 respectively. Here, we see the 
expected trend where there is an apparent increase in growth rate in the tsRNA 
overexpressed populations compared to the mock and negative controls. These results are 
complementary to our central hypothesis that ts-2 and  ts-112 promote cancer 
phenotypes.  
3.9: Overexpression of ts-2 or ts-112 in MCF10A cells has no effect on cell migration 
and invasion  
To assess the migratory ability of MCF10A cells after overexpression of tsRNA 


























Figure 3.8: Ts-2 or ts-112 overexpression in MCF10A cells results in an apparent 
trend of increased cell proliferation compared to control groups. 
Following a 4-hour transfection of ts-2 or ts-112 mimics, MCF10A cells were plated at 
equal density and CCK-8 cell proliferation assay performed by measuring absorbance at 
450 nm following the addition of an electron mediator, tetrazolium salt (WST-8). 
Absorbance values are related to viable cell counts. It appears that the ts-2 or ts-112 
mimic populations have an increased number of viable cells compared to the control 
populations, although there are no significant values when test groups are compared to 












Table 3.22: Absorbance (OD 450 nm) 
Absorbance values read at OD 450 nm have been normalized to wells with only media 
and WST-8 to eliminate background. Values reported represent the background 
corrected mean of triplicate wells per experiment. 
Table 3.23: Mean and Standard Error of the Mean  
Time 
(Hours) 
Mock Negative Control 
Mean SEM Mean SEM 
0 0.026 0.016 0.033 0.021 
24 0.180 0.082 0.237 0.099 
48 0.684 0.256 0.816 0.316 
72 1.251 0.349 1.409 0.302 
Mean and SEM of 3 independent experiments performed in triplicates. 
 

















0 0.783 0.454 0.256 0.714 0.380 
24 0.681 0.234 0.254 0.519 0.378 
48 0.763 0.280 0.262 0.508 0.422 
72 0.749 0.344 0.360 0.500 0.517 
Time 
(Hours) 
Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 Expt. 3 
0 -0.005 0.049 0.033 -0.001 0.031 0.070 
24 0.018 0.284 0.238 0.073 0.222 0.416 
48 0.184 1.032 0.837 0.295 0.765 1.387 
72 0.582 1.414 1.757 0.855 1.478 1.895 
Time 
(Hours) 
Mock Negative Control 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2  Expt. 3 
0 0.017 0.050 0.062 0.025 0.059 0.113 
24 0.216 0.340 0.393 0.194 0.340 0.770 
48 0.728 1.138 1.388 0.701 1.153 1.790 
72 1.607 1.417 1.963 1.523 1.411 2.071 
Time 
(Hours) 
Ts-2 Mimic Ts-112 Mimic 
Mean SEM Mean SEM 
0 0.043 0.013 0.066 0.026 
24 0.316 0.052 0.435 0.173 
48 1.085 0.192 1.215 0.316 
72 1.662 0.160 1.668 0.204 
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into the cells for 4 hours using Lipofectamine 3000. Cells (50,000 cells/well) in serum 
free media were plated into migration (control) chambers and invasion (matrigel) 
chambers of a transwell plate and allowed to migrate to through the membrane into full 
media for 24 hours. At the appropriate time point, cells were fixed and stained for 
imaging. Here, in the migration model, there appears to be no movement of cells from the 
inserts with no serum to the wells with full serum media (Figure 3.9). There does appear 
to be a slight increase in the invasive ability of MCF10A cells after overexpression of ts-
112 (Figure 3.9). As these cells are normal-like, these results make sense for the mock 
and negative control population. However, if tsRNA overexpression is supposed to 
increase cancer characteristics of these cells, it would be expected that invasion and 
migration in the ts-2 or ts-112 overexpressed populations would increase, which was the 
case only for the ts-112 population in the invasion plates. These results increase our 
confidence that ts-112 is related to promoting cancer phenotypes.  
3.10 Results Discussion: 
Cell Growth 
The first characteristic of cancer cells that we investigated is the ability to 
proliferate indefinitely, despite the presence of growth inhibitors. If our central 
hypothesis is true, that either ts-2 or ts-112 regulate cell growth to promote tumor cell 
aggressiveness, inhibition of ts-2 or ts-112 would lead to a decrease in MCF10CA1a cell 
growth over time. In our trypan blue exclusion growth curve, MCF10CA1a cells were 





   
 
Figure 3.9 Ts-2 or ts-112 overexpression of MCF10A cells has no effect on cell 
migration or invasion. 
A. Cell migration was assessed using control inserts in a trans-well assay. Pictures depict 
cells after 24 hour migration. No cells migrated from the well inserts into the well 
bottoms, indicating no migration of MCF10A cells, no matter the tsRNA content (n=1). 
B. Cell invasion was assessed using matrigel lined inserts in a trans-well assay. Pictures 
depict cells after 24 hour invasion. Ts-112 overexpressed cells appear to invade more 





With Dharmacon miRIDIAN, custom hairpin inhibitors of the two tsRNA 
molecules of interest, population growth appeared to decrease over time (Figure 3.1). 
While the decrease in population growth over time did not reach a significant level, the 
growth rate did decrease, especially between the 48- and 72-hour time points. The cell 
number of the ts-2 inhibited population is on average 22.6% less than that of the mock  
population at 72-hours (Table 3.2). The cell number of the ts-112 inhibited population is 
on average 17.6% less than that of the mock population at 72-hours (Table 3.2). There is 
a suggestive decrease (p<0.093) in population growth at 24-hours for the ts-112 inhibited 
population (Table 3.3) that indicates that the inhibition of ts-112 slows population growth 
rate within the first two doublings of the cells. The decreased population growth is 
sustained throughout the 72-hours (with decreased rates most prominent between 48- and 
72-hours) indicating that the inhibition of ts-2 or ts-112 lasts after multiple cell divisions. 
These data, though significance was not reached, suggest agreement with our central 
hypothesis that ts-2 or ts-112 promote breast cancer disease progression. It is also 
important to note that this experiment was performed in similar fashion by previous 
members of our lab, who observed similar results. 
In contrast, when the same trypan blue exclusion growth curve experiments were 
performed using the antisense oligonucleotide, Ambion mirVana inhibitors, there was no 
apparent difference in population growth over time in the ts-2 or ts-112 inhibited 
populations compared to the control groups (Figure 3.2). Differences in the Dhamacon 
miRIDIAN and Ambion mirVana inhibitor mechanisms of action could explain why 
these assays portray different results. Further, during transfections, miscalculations led to 
52 
 
using only half the concentration of Ambion mirVana inhibitors (25 nM) compared to 
Dharmacon miRIDIAN inhibitors (50 nM), which could also explain why our 
observation of decreased population growth vanished with mirVana inhibitors. 
To increase our confidence that ts-2 or ts-112 play a role in regulating population 
growth rate over time, the cell counting kit-8 assay was performed using the same 
inhibitors used in the trypan blue exclusion assays. Here, absorbance values read on a 
plate reader are correlated to cell proliferation; a higher absorbance reading indicates 
more cells in the population. With the Dhamacon miRIDIAN custom hairpin inhibitors, 
absorbance values were about the same for all test groups throughout all time periods 
(Figure 3.3). There is a suggestive (p<0.1) decrease in absorbance in the ts-112 
population at 72-hours (Table 3.9). With the Ambion mirVana antisense oligonucleotide 
inhibitors, however, there is a significant decrease (p<0.05) in proliferation in the ts-112 
inhibited population at the 48- and 72- hour time points when compared to the mock 
population (Figure 3.4, Table 3.12). Decrease in absorbance readings throughout the 72-
hour time course indicates that the tsRNA inhibition lasts beyond a few population 
doublings. These CCK-8 assays depicting a decrease in population proliferation rates 
over time agree with our central hypothesis that ts-2 or ts-112 regulate cell growth to 
promote cancer characteristics. These results suggest that tsRNAs, especially ts-112, 
promote cancer cell growth. 
If our central hypothesis is true, and ts-2 or ts-112 regulate cell growth to promote 
aggressive breast cancer disease progression, overexpression of ts-2 or ts-112 would lead 
to an increase in growth in the MCF10A cells. In our trypan blue exclusion growth curve, 
53 
 
MCF10A cells were transfected with 25 nM Ambion mirVana oligonucleotide mimics of 
ts-2 or ts-112 and allowed to grow over a 72-hour time course. With Ambion mirVana 
oligonucleotide mimics of the two tsRNA molecules of interest, population growth 
appeared to decrease over time (Figure 3.7). Changes in population growth over time 
between the groups did not reach significance, however. Repeating this experiment in 
attempt to limit the error is important to better understand the results of this assay.  
In parallel with our first aim and to increase our confidence that ts-2 or ts-112 
play a role in regulating population growth rate over time, the cell counting kit-8 assay 
was performed using the same mimics used in the trypan blue exclusion assays. Here, 
absorbance values read on a plate reader are correlated to cell proliferation; a higher 
absorbance reading indicates more cells in the population. With Ambion mirVana 
oligonucleotide mimics of ts-2 or ts-112, absorbance values appear to increase compared 
to the control populations (Figure 3.8). Although the differences in absorbance readings 
did not reach significance, the ts-2 overexpressed population has an average absorbance 
that is 16.4% higher than the mock at 72-hours (Table 3.21). Similarly, the ts-112 
overexpressed population has an average absorbance that is 13.8% less than the mock at 
72-hours (Table 3.21). The CCK-8 assays depicting an increase in population 
proliferation rates over time agree with our central hypothesis that ts-2 or ts-112 regulate 
cell growth to promote cancer characteristics. These results suggest that tsRNAs promote 




Cell Cycle Regulation 
 After observing an increase in cell growth and proliferation with the trypan blue 
exclusion growth curves and CCK-8 assays following ts-2 or ts-112 inhibition of 
MCF10CA1a cells, we questioned if this was due to tsRNAs playing a role in cell cycle 
regulation. After a 24-hour transfection with Dharmacon miRIDIAN inhibitors of ts-2 or 
ts-112, the cell cycle of MCF10CA1a cells was analyzed using flow cytometry. Here, we 
observed an increase in S phase and a decrease in G1 phase of cells following ts-2 or ts-
112 inhibition compared to the mock and negative control populations. This indicates that 
cells are dividing less, spending more time in S phase, which is responsible for DNA 
replication in preparation for mitosis. Through this experiment, we understood more 
clearly that ts-2 or ts-112 play a role in increasing population doubling time, by 
increasing up the amount of time cells spend in S phase.  
Cell Death 
 In order to understand if ts-2 or ts-112 are involved in regulating cancer cell 
death, cell death percentages generated from the trypan blue exclusion growth curve were 
analyzed and compared between groups over a 72-hour time course. Cancer cells can 
ignore apoptosis signals and continue to grow. If ts-2 or ts-112 promote cancer cell 
characteristics, it would be expected that there would be an increase in cell death when ts-
2 or ts-112 are inhibited in MCF10CA1a cells. This was not the case. There is no change 
in cell death between the tsRNA inhibited populations when compared to the control 
populations. Ts-2 or ts-112 molecules may promote cancer phenotypes by increasing 
population doubling time (seen in cell cycle analysis) and increasing proliferation rate 
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(seen in growth curves and CCK-8 assays), but these molecules are not involved in 
evading cell death.  
Cell Migration and Invasion 
 Cancer cells can migrate to a location in the body where they did not originate. 
This migratory capability is known as metastasis and is a characteristic of aggressive, 
stage IV cancer types. To further understand the role of ts-2 or ts-112 in aggressive breast 
cancer, MCF10CA1a cells were transfected with Ambion mirVana antisense 
oligonucleotide inhibitors of ts-2 or ts-112 and plated in a trans-well plate to assess 
migration. Results of our trans-well assay for cell migration did not reflect our 
expectations. Since cancer cells can migrate and metastasize, we expected the mock and 
negative control populations to migrate. If ts-2 or ts-112 are supposed to promote cancer 
cell characteristics, then the inhibited populations would show a decrease in cell 
migration compared to the mock and control. However, there was no changes in cell 
migration in our ts-2 or ts-112 inhibited populations compared to the control groups 
(Figure 3.6). Although this experiment was only performed once (n=1), it could be 
assumed that ts-2 or ts-112 have no effect on cancer cells ability to migrate. These results 
do not support our central hypothesis that ts-2 or ts-112 promote cancer characteristics. 
To keep our experiments consistent between the two aims of the project, we 
evaluated the ability of MCF10A cells to migrate in a trans-well assay following ts-2 or 
ts-112 overexpression. MCF10A cells were transfected with Ambion mirVana 
oligonucleotide mimics of ts-2 or ts-112 and plated in a trans-well plate to assess 
migration. Results of our trans-well assay for cell migration again did not reflect our 
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expectations. Since cancer cells can migrate and metastasize more easily than normal like 
cells, we expected the mock and negative control populations to remain in low serum 
media, without migrating into full serum media. If ts-2 or ts-112 are said to promote 
cancer cell characteristics, then the overexpressed populations would show an increase in 
cell migration compared to the mock and control. However, there was no changes in cell 
migration in our ts-2 or ts-112 inhibited populations compared to the control groups 
(Figure 3.10A). Although this experiment was only performed once (n=1), it could be 
assumed that ts-2 or ts-112 have no effect on cancer cells ability to migrate. An invasion 
assay, involving a Matrigel-lined trans-well insert was also performed. This experiment 
resulted in an increase in cell invasion in the ts-112 overexpressed group (Figure 3.9B). 







CHAPTER 4: DISCUSSION 
4.1 Background and Project Overview 
 In the United States, 1 in 8 women will be diagnosed with breast cancer at some 
point in her life (1). The five-year survival rate of stage IV disease remains less than 30% 
(1, 2). There remains a need for a better understanding of the molecular mechanisms 
driving stage IV disease to improve the overall survival rates of patients diagnosed with 
aggressive breast cancer. It has been recently discovered that tRNA-derived small RNA 
(tsRNA) molecules are dysregulated in breast cancer. To elucidate the molecular 
mechanisms driving breast cancer, the Stein/Lian research group profiled 113 established 
tsRNAs in MCF10A, MCF10AT1, MCF7, MCF10CA1a, and MDA-MB-231 cell lines 
and H9 female human embryonic stem cells (hESC). Two tsRNAs, ts-2 and ts-112, have 
relatively low levels in the normal-like, mammary epithelial MCF10A cells and high 
levels in MCF10CA1a and MDA-MB-231 aggressive breast cancer cell lines (3). Further, 
H9 hESCs express high levels of ts-2 and ts-112. Studies have identified many genes 
highly expressed in hESCs to be upregulated in cancer cells (3). For this reason, ts-2 and 
ts-112 were chosen for our studies. 
The central hypothesis of this project stated that ts-2 and ts-112 regulate cell 
growth, death, migration, and the invasive ability to promote breast cancer progression to 
aggressive disease. We tested our hypothesis in Aim 1, identify the functions of ts-2 and 
ts-112 in aggressive breast cancer, by inhibiting ts-2 and ts-112 in the MCF10CA1a 
aggressive breast cancer cell line. In Aim 2, determine the ability of ts-2 and ts-112 to 
promote breast cancer characteristics in the normal mammary epithelium, we 
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overexpressed ts-2 and ts-112 with mimics in the MCF10A normal-like mammary 
epithelial cell line. Here, we will address the results in relation to the central hypothesis, 
in attempt to understand how tsRNA molecules regulate cancer progression. With 
successful completion of this project, we now have a greater understanding of tsRNA 
molecules and their roles in driving aggressive breast cancer. Our findings, supporting 
our hypothesis or not, have a positive impact in the search to identify new molecular 
targets for precision treatment approaches against aggressive breast cancer. 
To identify the functions of ts-2 and ts-112 in aggressive breast cancer (Aim 1), 
experiments were performed in the MCF10CA1a cell line to inhibit ts-2 and ts-112. 
MCF10CA1a cells are representative of aggressive breast cancer and ts-2 and ts-112 
levels are highly expressed in this cell type compared to both normal-like breast cells and 
cells representative of stage I-III breast cancer (3). Here, we compared different custom 
ts-2 or ts-112 inhibitors with unique mechanisms of action that were purchased from two 
different companies. Dharmacon miRIDIAN inhibitors were designed to be single-
stranded RNA molecules with complementary sequences to ts-2 or ts-112, with both 5’ 
and 3’ RNA hairpin structures. Ambion mirVana inhibitors were designed as single 
stranded RNA molecules complementary to ts-2 or ts-112 with modified RNA bases for 
stability. To determine the ability of ts-2 or ts-112 to promote breast cancer 
characteristics in the normal mammary epithelium (Aim 2), experiments were performed 
in the MCF10A cell line following overexpression of ts-2 or ts-112. MCF10A cells are 
representative of cells in the normal mammary epithelium and ts-2 and ts-112 levels are 
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low in these cells. Here, we used custom Ambion mirVana mimics to overexpress ts-2 or 
ts-112.  
We assessed population cell growth/death using both trypan blue exclusion and 
the Cell Counting Kit-8 (CCK-8) assay and observed that tsRNA levels alter growth rate 
to promote cancer characteristics. Further evidence that ts-2 and ts-112 promote cancer 
characteristics was shown via an increase in population percentage in S phase and a 
decrease in population percentage in G1 phase following ts-2 or ts-112 inhibition of 
MCF10CA1a cells assessed using flow cytometry. In addition, we investigated cell 
migration and invasion using trans-well assays, but there was little evidence that ts-2 or 
ts-112 manipulation results in any migration/invasion activity of MCF10A or 
MCF10CA1a cells.  
4.2 TsRNAs responsive to tumor suppressors could explain changes in cell cycle 
 Thu, et al, 2018, describes changes in the cell cycle in breast cancer cells (4). 
Transitions through the cell cycle from one phase to another are dependent on satisfying 
checkpoints. One way that cancer cells grow uncontrollably is by evading the 
checkpoints and progressing through the cycle anyway. Targeting the cell cycle is an 
important technique in treating breast cancer. 
A recent publication from the Stein/Lian research group, Farina et. al, 2020, 
established a connection between runt-related transcription factor-1 (RUNX1) and 
tsRNAs (5). The paper identified four tsRNA molecules, including ts-112, that were 
responsive to the tumor suppressor, RUNX1, in breast cancer. RUNX1 is a key 
transcription factor in breast cancer initiation and progression. There is evidence that this 
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tumor suppressor maintains the mammary epithelium by regulating tsRNA expression 
levels. The authors concluded that ts-112 is oncogenic, and RUNX1 acts as a tumor 
suppressor by inhibiting ts-112 to maintain the mammary epithelium.  
 Although RUNX1 was the only transcription factor reported in the publication to 
have a regulatory capacity on tsRNA molecules, it is not to say that other transcription 
factors don’t also interrupt or promote tsRNA activity. Tumor protein p53 is a tumor 
suppressor involved in regulating the cell cycle at the G1/S checkpoint. DNA damage 
leads to increased expression of the p53 gene, which acts to prevent the cell from entering 
the S phase of the cell cycle to allow time for DNA repair. P53 mutations are common in 










Figure 4.1: TsRNAs may interrupt the binding between p53 and mdm2 
Data from our cell proliferation and cell cycle assays provide evidence that results 
from tsRNA manipulation could be linked to p53 involvement. The ubiquitin ligase 
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protein, mdm2, is responsible for binding to and inhibiting p53 activity in healthy cells. It 
is possible that ts-2 or ts-112 have a role in degrading p53, therefore allowing for the cell 
cycle to continue. To test this theory, studies could be performed to evaluate the integrity 
of p53/mdm2 binding in the presence or absence of ts-2 or ts-112. Future studies 
involving tsRNA molecules and various tumor suppressor molecules are important in 
order to understand the role of tsRNAs in the molecular mechanisms driving aggressive 
breast cancer.  
Our data indicated a potential increase in S phase and a decrease in G1 phase in 
the cell population following ts-2 or ts-112 inhibition of MCF10CA1a cells. This 
indicates the potential ability if cells to ignore G1/S checkpoint proteins. E2F is a group 
of genes upstream of p53 that encodes proteins responsible for the transition from the G1 
phase to S phase. It is possible that ts-2 and ts-112 are responsible for repressing E2F 
activity, and thus inhibition of ts-2 or ts-112 leads to an increased percentage of cells 
entering the S phase.  
4.3 TsRNAs potential involvement in cancer diagnosis and treatment 
 In Balatti, et. al, 2017, the authors study various tsRNA molecules involved in 
different cancer types (3). Their experiments provide evidence that tsRNAs are involved 
in different stages of cancer progression. While some tsRNAs (ex. ts-36 in colon cells) 
are not expressed in adenomas, they are upregulated in carcinomas, suggesting that they 
are involved in the progression of benign tumors into malignant ones (3). Like in Farina 
et. al, 2019, experiments involving various tumor suppressors were shown to manipulate 
tsRNA expression levels.  
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Our data provide evidence ts-2 and ts-112 are upregulated in cancer cell models 
compared to the normal like cell line MCF10A. MCF10CA1a aggressive breast cancer 
cells grow slower when ts-2 or ts-112 are inhibited, indicating that tsRNA inhibitors 
could potentially be used as targeted treatment of some cancers to decrease disease 
progression over time. These data are supportive of the idea that future diagnosis 
strategies and treatment therapies could take advantage of this active crosstalk between 
tsRNAs and oncogenes.  
4.4 Conclusions and Future Directions 
Based on the results of the experiments performed, the main conclusion of this 
project is the ts-112 is oncogenic and promotes cell proliferation. In our cell growth 
experiments, ts-112-inhibited MCF10CA1a populations showed a decrease in cell growth 
rate over time and ts-112-overexpressed MCF10A populations showed an increase in cell 
growth rate over time. To improve this project, studies in the future could evaluate the 
role of ts-112 on regulating cell cycle checkpoint genes. Perhaps the change in the cell 
cycle seen in ts-112-inhibited MCF10CA1a populations could be explained by ts-112 
altering mechanisms of checkpoint genes, allowing the cells to continue to grow and 
divide (seen with an increase in S phase). Furthermore, studies to determine tsRNA 
binding partners is important when discussing the future of this project. Both 
computational predictions of RNA:RNA interactions as well as RNA 
immunoprecipitation for potential involvement in RNA-induced silencing complex 
(RISC) could help further explain the role of tsRNAs in promoting cancer phenotypes. 
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TsRNA research is still new. Not many groups have published work on these 
molecules. Once there is a greater understanding of ts-2, ts-112, and tsRNAs in general, 
we are hopeful that there will be a greater understanding of the molecular mechanisms 
driving aggressive breast cancers. It is important to understand these molecular 
mechanisms in order to someday increase the 5-year survival prognosis for individuals 
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